GSK (GSK) — Dividend Yield: 3.20%

GSK plc (LON: GSK) is a leading global pharmaceutical and biotechnology company listed on the FTSE 100, with a market capitalisation of approximately £84.0 billion. Following the demerger of its consumer healthcare business as Haleon in 2022, GSK has been refocused as a pure-play biopharma company concentrating on innovative medicines and vaccines. The company's therapeutic areas include infectious diseases, HIV, oncology, and immunology, with a pipeline of over 70 potential new medicines and vaccines.

GSK's dividend yield of approximately 3.20% provides a competitive income stream for healthcare sector investors. Following the Haleon separation, GSK rebased its dividend to reflect its new focused structure, but the payout remains attractive relative to the pharmaceutical sector average. The company has signalled its intention to grow the dividend progressively as earnings improve, supported by new product launches and commercial execution.

For investors looking to add pharmaceutical stocks to their FTSE 100 portfolio, GSK offers a compelling blend of income and growth potential. The company's HIV franchise, led by its majority-owned ViiV Healthcare subsidiary, generates substantial recurring revenues with high margins. GSK's vaccines division, which includes the blockbuster shingles vaccine Shingrix, provides additional defensive revenue streams with significant growth potential in both developed and emerging markets.

GSK's investment in research and development has accelerated significantly, with a focus on oncology where the company sees its greatest growth opportunity. The acquisition of Sierra Oncology and collaboration agreements with multiple biotech companies have strengthened its cancer treatment pipeline. GSK's respiratory portfolio, while mature, continues to generate significant cash flows. With a renewed strategic focus, growing pipeline, and steady dividend, GSK represents an attractive option for investors seeking healthcare exposure with income potential in the FTSE 100.